Marina Pulido

Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas

Maud Toulmonde, Nicolas Penel, Julien Adam et al. · JAMA Oncology · 2017 · 381 citations · Full text

Pazopanib or methotrexate–vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study

Maud Toulmonde, Marina Pulido, Isabelle Ray‐Coquard et al. · The Lancet Oncology · 2019 · 193 citations · Full text

Oncology, Combination Chemotherapy, Metronomic Therapy +8

Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: Formal consensus method for the development of guidelines for standardised time-to-event endpoints’ definitions in cancer clinical trials

Carine Bellera, Marina Pulido, Sophie Gourgou et al. · European Journal of Cancer · 2012 · 64 citations

Time-to-event Endpoints, Clinical Trial Design, Oncology +14

Diagnostic accuracy of 18F-FDG PET/CT for assessing response to radiofrequency ablation treatment in lung metastases: a multicentre prospective study

F. Bonichon, Jean Palussière, Yann Godbert et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2013 · 42 citations

Positron Emission Tomography, 18F-fdg Pet/ct, Nuclear Medicine +10

Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer

Marina Pulido, Guilhem Roubaud, Anne‐Laure Cazeau et al. · BMC Cancer · 2018 · 29 citations · Full text